GRFに対するGH反応がdopamineにより消失し, sulpirideでは変化しなかった末端肥大症の一例
スポンサーリンク
概要
- 論文の詳細を見る
Inhibition of plasma GH by dopaminergic agonists is one of the characteristics of the GH secretion in acromegaly. GRF is known to stimulate GH secretion in most patients with acromegaly. In order to elucidate the relationship between GRF and dopamine in regulating the secretion of GH in this disease, we examined plasma GH responses to dopamine (DA) infusion (4μEg/kg/min), GRF injection (100μEg i.v.), sulpiride (SP) injection (200mg i.v.), a DA blocker, DA plus GRF and SP plus GRF in a 51-year-old male patient with acromegaly.<BR>Plasma GH was reduced to 14% of the initial level by iv infusion of DA, and was elevated to 158% by iv injection of GRF. No considerable change was observed in plasma GH by iv infusion of SP (114% of the initial level). GH release induced by GRF was remarkably reduced by simultaneous administration of DA (28% of the initial level), whereas SP administration did not affect GRF-induced GH release (154%). The marked reduction of GH release after DA plus GRF seems to suggest that the effect of DA on the GH regulation is stronger than that of GRF in this acromegalic patient. It is suggested also that endogenous DA may not play an inhibitory role in GH secretion in this case since DA blockade by SP did not raise basal GH levels and the GH response to GRF.
- 一般社団法人 日本内分泌学会の論文
著者
関連論文
- 成長因子としてのトランスフェリン測定の臨床的意義:第一報 : 下垂体疾患治療前後での変化
- 成長因子としてのトランスフェリン測定の臨床的意義:第二報 : 各種内分泌状態における変化
- GRFに対するGH反応がdopamineにより消失し, sulpirideでは変化しなかった末端肥大症の一例
- LHRH superanalogue点鼻投与の内因性LHRH, ゴナドトロピンに及ぼす影響